Compare VYGR & RGCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VYGR | RGCO |
|---|---|---|
| Founded | 2013 | 1912 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Oil & Gas Production |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 236.0M | 233.9M |
| IPO Year | 2015 | 2005 |
| Metric | VYGR | RGCO |
|---|---|---|
| Price | $3.95 | $23.35 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 1 |
| Target Price | $21.00 | ★ $22.70 |
| AVG Volume (30 Days) | ★ 624.9K | 8.2K |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 3.75% |
| EPS Growth | N/A | ★ 11.21 |
| EPS | N/A | ★ 0.47 |
| Revenue | $10,135,000.00 | ★ $95,334,212.00 |
| Revenue This Year | $34.04 | $11.06 |
| Revenue Next Year | $7.92 | $2.89 |
| P/E Ratio | ★ N/A | $49.87 |
| Revenue Growth | N/A | ★ 12.63 |
| 52 Week Low | $2.65 | $19.68 |
| 52 Week High | $5.55 | $24.00 |
| Indicator | VYGR | RGCO |
|---|---|---|
| Relative Strength Index (RSI) | 50.43 | 58.59 |
| Support Level | $3.72 | $20.67 |
| Resistance Level | $4.30 | $23.79 |
| Average True Range (ATR) | 0.22 | 0.71 |
| MACD | -0.01 | 0.20 |
| Stochastic Oscillator | 55.45 | 68.37 |
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.
RGC Resources Inc is involved in the business of distribution and sale of natural gas to residential, commercial, and industrial customers within its service territory in Roanoke, Virginia, and its surrounding localities. The company also provides certain non-regulated services. The company relies on multiple interstate pipelines to transport natural gas. The company operates in three segments: Gas Utility, which is the key revenue generator; Investment in Affiliates this segment reflects the income generated through the activities of the Company's investment in MVP and Southgate projects and Parent & Other including the unregulated activities of the Company as well as certain corporate eliminations.